These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 19619690)

  • 1. Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study.
    Pratt CM; Reiffel JA; Ellenbogen KA; Naccarelli GV; Kowey PR
    Am Heart J; 2009 Aug; 158(2):163-169.e1-3. PubMed ID: 19619690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rationale and design of the FORomegaARD Trial: A randomized, double-blind, placebo-controlled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation.
    Macchia A; Varini S; Grancelli H; Nul D; Laffaye N; Ferrante D; Tognoni G; Doval HC;
    Am Heart J; 2009 Mar; 157(3):423-7. PubMed ID: 19249410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
    Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial.
    Kowey PR; Reiffel JA; Ellenbogen KA; Naccarelli GV; Pratt CM
    JAMA; 2010 Dec; 304(21):2363-72. PubMed ID: 21078810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.
    Rupp H
    Adv Ther; 2009 Jul; 26(7):675-90. PubMed ID: 19629408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study.
    Bianconi L; Calò L; Mennuni M; Santini L; Morosetti P; Azzolini P; Barbato G; Biscione F; Romano P; Santini M
    Europace; 2011 Feb; 13(2):174-81. PubMed ID: 21059740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter.
    Hohnloser SH; Connolly SJ; Crijns HJ; Page RL; Seiz W; Torp-Petersen C
    J Cardiovasc Electrophysiol; 2008 Jan; 19(1):69-73. PubMed ID: 18031520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of a randomized clinical trial to assess the role of overdrive and triggered prevention pacing therapies in reducing atrial fibrillation: the Study of Atrial Fibrillation Reduction (SAFARI).
    Gold MR; Hoffmann E;
    Am Heart J; 2006 Aug; 152(2):231-6. PubMed ID: 16875902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.
    Roy D; Rowe BH; Stiell IG; Coutu B; Ip JH; Phaneuf D; Lee J; Vidaillet H; Dickinson G; Grant S; Ezrin AM; Beatch GN;
    J Am Coll Cardiol; 2004 Dec; 44(12):2355-61. PubMed ID: 15607398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marine n-3 fatty acids, atrial fibrillation and QT interval in haemodialysis patients.
    Kirkegaard E; Svensson M; Strandhave C; Schmidt EB; Jørgensen KA; Christensen JH
    Br J Nutr; 2012 Mar; 107(6):903-9. PubMed ID: 21791142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial.
    Kirchhof P; Fetsch T; Hanrath P; Meinertz T; Steinbeck G; Lehmacher W; Breithardt G
    Am Heart J; 2005 Nov; 150(5):899. PubMed ID: 16290956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.
    Connolly SJ; Crijns HJ; Torp-Pedersen C; van Eickels M; Gaudin C; Page RL; Hohnloser SH;
    Circulation; 2009 Sep; 120(13):1174-80. PubMed ID: 19752319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial.
    Goette A; Schön N; Kirchhof P; Breithardt G; Fetsch T; Häusler KG; Klein HU; Steinbeck G; Wegscheider K; Meinertz T
    Circ Arrhythm Electrophysiol; 2012 Feb; 5(1):43-51. PubMed ID: 22157519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial.
    Macchia A; Grancelli H; Varini S; Nul D; Laffaye N; Mariani J; Ferrante D; Badra R; Figal J; Ramos S; Tognoni G; Doval HC;
    J Am Coll Cardiol; 2013 Jan; 61(4):463-468. PubMed ID: 23265344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
    Disertori M; Latini R; Maggioni AP; Delise P; Di Pasquale G; Franzosi MG; Staszewsky L; Tognoni G;
    J Cardiovasc Med (Hagerstown); 2006 Jan; 7(1):29-38. PubMed ID: 16645357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and rationale of a randomized study to compare amiodarone and Class IC anti-arrhythmic drugs in terms of atrial fibrillation treatment efficacy in patients paced for sinus node disease: the PITAGORA trial.
    Gulizia M; Mangiameli S; Chiarandà G; Spadola V; Di Giovanni N; Colletti A; Bulla V; Circo A; Pensabene O; Vasquez L; Vaccaro I; Grammatico A;
    Europace; 2006 Apr; 8(4):302-5. PubMed ID: 16627459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Right atrial preventive and antitachycardia pacing for prevention of paroxysmal atrial fibrillation in patients without bradycardia: a randomized study.
    Hemels ME; Ruiter JH; Molhoek GP; Veeger NJ; Wiesfeld AC; Ranchor AV; van Trigt M; Pilmeyer A; Van Gelder IC; ;
    Europace; 2008 Mar; 10(3):306-13. PubMed ID: 18245199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conventional and dedicated atrial overdrive pacing for the prevention of paroxysmal atrial fibrillation: the AFTherapy study.
    Camm AJ; Sulke N; Edvardsson N; Ritter P; Albers BA; Ruiter JH; Lewalter T; Capucci PA; Hoffmann E;
    Europace; 2007 Dec; 9(12):1110-8. PubMed ID: 18042619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy.
    Singh SN; Tang XC; Singh BN; Dorian P; Reda DJ; Harris CL; Fletcher RD; Sharma SC; Atwood JE; Jacobson AK; Lewis HD; Lopez B; Raisch DW; Ezekowitz MD;
    J Am Coll Cardiol; 2006 Aug; 48(4):721-30. PubMed ID: 16904540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis.
    Burgess DC; Kilborn MJ; Keech AC
    Eur Heart J; 2006 Dec; 27(23):2846-57. PubMed ID: 17015402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.